# Solid Biosciences Inc.: overview SLDB · Nasdaq · CIK 1707502 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sldb.md) · [Financials](/companies/sldb/financials.md) · [Filings](/companies/sldb/filings.md) · [Insiders](/companies/sldb/insiders.md) Latest reported revenue: [$0](/filings/0001564590-22-009963.md) for Q4 FY2020, three months to 2020-12-31, from the 10-K filed Mar 14, 2022 (XBRL us-gaap:Revenues, accession 0001564590-22-009963). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.79)](/filings/0001193125-25-262818.md) | not reported | [(0.59)](/filings/0001193125-26-219337.md) | [(0.42)](/filings/0001193125-26-337935.md) | [(0.48)](/filings/0001193125-25-262818.md) | not reported | [(0.52)](/filings/0001193125-26-219337.md) | [(0.38)](/filings/0001193125-26-337935.md) | | Free cash flow | $m | [(23.7) d](/filings/0001193125-25-262818.md) | [(29.8) d](/filings/0001193125-26-115928.md) | [(32.0)](/filings/0001193125-26-219337.md) | [(37.8) d](/filings/0001193125-26-337935.md) | [(33.6) d](/filings/0001193125-25-262818.md) | [(54.1) d](/filings/0001193125-26-115928.md) | [(47.4)](/filings/0001193125-26-219337.md) | [(52.7) d](/filings/0001193125-26-337935.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [13.6](/filings/0000950170-23-009318.md) | [8.1](/filings/0000950170-23-009318.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(530.5%)](/filings/0000950170-24-030508.md) | [(1315.2%)](/filings/0000950170-24-030508.md) | not reported | not reported | not reported | | Net margin | % | [(530.0%)](/filings/0000950170-24-030508.md) | [(1062.3%)](/filings/0000950170-24-030508.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(10.14)](/filings/0000950170-24-030508.md) | [(10.10)](/filings/0000950170-24-030508.md) | [(4.83)](/filings/0000950170-25-034644.md) | [(3.06)](/filings/0001193125-26-115928.md) | [(1.99)](/filings/0001193125-26-115928.md) | | Free cash flow | $m | [(79.0)](/filings/0000950170-24-030508.md) | [(101)](/filings/0000950170-24-030508.md) | [(95.7)](/filings/0000950170-25-034644.md) | [(101)](/filings/0001193125-26-115928.md) | [(157)](/filings/0001193125-26-115928.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sldb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $120.2m | 12,036,126 | | Added +2,696,148 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $118.9m | 11,906,646 | | Unchanged | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $98.0m | 9,808,819 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $76.8m | 7,690,405 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $69.3m | 6,934,248 | | Added +1,975,894 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $68.7m | 6,875,957 | | Added +3,269,553 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $42.7m | 4,278,000 | | Added +1,078,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $41.7m | 4,175,365 | | Added +3,049,878 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $40.4m | 4,043,605 | | Not compared | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $40.1m | 4,009,922 | | Added +1,335,298 | ## Recent filings [All 730 filings](/companies/sldb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 17:22 ET | [SCHEDULE 13D/A](/filings/0001193125-26-352656.md) | Ownership report, active investor, amended | 0001193125-26-352656 | | 2026-08-06 | 17:15 ET | [8-K](/filings/0001193125-26-338438.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-338438 | | 2026-08-06 | 16:04 ET | [10-Q](/filings/0001193125-26-337935.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337935 | | 2026-06-24 | 18:49 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000183.md) | Ownership report, active investor, amended | 0001346824-26-000183 | | 2026-06-10 | 16:05 ET | [8-K](/filings/0001193125-26-265804.md) | 5.07 Shareholder vote results | 0001193125-26-265804 | | 2026-05-12 | 16:02 ET | [10-Q](/filings/0001193125-26-219337.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219337 | | 2026-04-23 | 16:03 ET | [DEF 14A](/filings/0001193125-26-173642.md) | Proxy statement, period 2026-06-10 | 0001193125-26-173642 | | 2026-04-10 | 16:09 ET | [8-K](/filings/0001193125-26-151259.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-151259 | | 2026-03-19 | 16:01 ET | [10-K](/filings/0001193125-26-115928.md) | Annual report, period 2025-12-31 | 0001193125-26-115928 | | 2026-03-17 | 18:50 ET | [SCHEDULE 13D/A](/filings/0001104659-26-029671.md) | Ownership report, active investor, amended | 0001104659-26-029671 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-115928.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1707502 - Tickers: SLDB - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:06 ET. No prices; not investment advice.